Table 2.
Predictive factors for identifying patients ineligible to receive reduced dose of cisplatin-based adjuvant chemotherapy#.
| Postoperative eGFR (mL/min/1.73 m2) | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| All | ≥45 | <45 | Chi-square | P value | OR | 95% CI | P value | |
| All, number (%) | 485 (100) | 375 (77.3) | 110 (22.3) | |||||
| Gender, number (%) | 0.685 | 0.236 | ||||||
| Male | 224 (46.2) | 177 (47.2) | 47 (42.7) | |||||
| Female | 261 (53.8) | 198 (52.8) | 63 (57.3) | |||||
| Age∧, number (%) | 6.773 | 0.006∗ | 0.999 | 0.996–1.003 | 0.922 | |||
| <70 | 260 (53.6) | 213 (56.8) | 47 (42.7) | |||||
| ≥70 | 225 (46.4) | 162 (43.2) | 63 (57.3) | |||||
| Preoperative eGFR (mL/min/1.73 m2)∧, number (%) |
34.365 | <0.001∗ | 0.991 | 0.989–0.993 | <0.001∗ | |||
| <60 | 353 (72.8) | 297 (79.2) | 56 (50.9) | |||||
| ≥60 | 132 (27.2) | 78 (20.8) | 54 (49.1) | |||||
| Previous or concomitant BT, number (%) | 0.004 | 0.546 | ||||||
| No | 418 (86.2) | 323 (86.1) | 95 (86.4) | |||||
| Yes | 67 (13.8) | 52 (13.9) | 15 (13.6) | |||||
| Side, number (%) | 0.645 | 0.244 | ||||||
| Left | 235 (48.5) | 178 (47.5) | 57 (51.8) | |||||
| Right | 250 (51.5) | 197 (52.5) | 53 (48.2) | |||||
| Location, number (%) | 9.325 | 0.002∗ | 1.164 | 1.074–1.262 | <0.001∗ | |||
| Ureter | 234 (48.2) | 195 (52.0) | 39 (35.5) | |||||
| Pelvis | 251 (51.8) | 180 (48.0) | 71 (64.5) | |||||
| Hydronephrosis, number (%) | 12.523 | <0.001∗ | 0.881 | 0.813–0.956 | 0.002∗ | |||
| No | 228 (47.0) | 160 (42.7) | 68 (61.8) | |||||
| Yes | 257 (53.0) | 215 (57.3) | 42 (38.2) | |||||
| Multifocality, number (%) | 0.853 | 0.215 | ||||||
| No | 398 (82.1) | 311 (82.9) | 87 (79.1) | |||||
| Yes | 87 (17.9) | 64 (17.1) | 23 (20.9) | |||||
| DM, number (%) | 0.091 | 0.444 | ||||||
| No | 401 (92.7) | 309 (82.4) | 92 (83.6) | |||||
| Yes | 84 (17.3) | 66 (17.6) | 18 (16.4) | |||||
| Hypertension, number (%) | 0.877 | 0.204 | ||||||
| No | 292 (60.2) | 230 (61.3) | 62 (56.4) | |||||
| Yes | 193 (39.8) | 145 (38.7) | 48 (43.6) | |||||
| Smoking, number (%) | 0.276 | 0.344 | ||||||
| No | 392 (80.8) | 305 (81.3) | 87 (79.1) | |||||
| Yes | 93 (19.2) | 70 (18.7) | 23 (20.9) | |||||
| Tumor size (cm)∧, number (%) | 16.163 | <0.001∗ | 0.969 | 0.955–0.983 | 0.001∗ | |||
| <3 | 267 (55.1) | 188 (50.1) | 79 (71.8) | |||||
| ≥3 | 218 (44.9) | 187 (49.9) | 31 (28.2) | |||||
| Architecture, number (%) | 13.392 | <0.001∗ | ||||||
| Papillary | 362 (74.6) | 266 (70.9) | 96 (87.3) | |||||
| Sessile | 117 (24.1) | 105 (28.0) | 12 (10.9) | |||||
| Stage, number (%) | 19.838 | <0.001∗ | ||||||
| Ta/T1/T2 | 330 (68.0) | 236 (62.9) | 94 (85.5) | |||||
| T3/T4 | 155 (32.0) | 139 (37.1) | 16 (14.5) | |||||
| Grade, number (%) | 9.525 | 0.001∗ | ||||||
| G1-2 | 282 (58.1) | 204 (54.4) | 78 (70.9) | |||||
| G3 | 203 (41.9) | 171 (45.6) | 32 (29.1) | |||||
| Tumor necrosis, number (%) | 3.385 | 0.043∗ | ||||||
| No | 436 (89.9) | 332 (88.5) | 104 (94.5) | |||||
| Yes | 49 (10.1) | 43 (11.5) | 6 (5.5) | |||||
| CIS, number (%) | 0.579 | 0.350 | ||||||
| Absent | 471 (97.1) | 363 (96.8) | 108 (98.2) | |||||
| Present | 14 (2.9) | 12 (3.2) | 2 (1.8) | |||||
*Statistically significant.
#Only patients with preoperative eGFR ≥ 45 mL/min/1.73 m2 were included.
∧Initially calculated as binary variables in univariate analysis and used as linear variable in multivariate analysis.
OR: odds ratio; CI: confidence interval; eGFR: estimated glomerular filtration rate; BT: bladder tumor; DM: diabetes mellitus; CIS: carcinoma in situ.